Royal Bank of Canada Reiterates “Outperform” Rating for Sarepta Therapeutics (NASDAQ:SRPT)

Royal Bank of Canada restated their outperform rating on shares of Sarepta Therapeutics (NASDAQ:SRPT) in a research report released on Monday morning, Benzinga reports. The firm currently has a $182.00 target price on the biotechnology company’s stock.

Other equities analysts have also recently issued reports about the stock. UBS Group boosted their target price on shares of Sarepta Therapeutics from $173.00 to $188.00 and gave the company a “buy” rating in a research note on Tuesday, September 17th. BMO Capital Markets increased their target price on shares of Sarepta Therapeutics from $170.00 to $200.00 and gave the stock an “outperform” rating in a research note on Monday, June 24th. Evercore ISI raised Sarepta Therapeutics from an “in-line” rating to an “outperform” rating and reduced their price target for the stock from $185.00 to $179.00 in a report on Thursday, August 8th. Cantor Fitzgerald reissued a “neutral” rating and issued a $152.00 price objective on shares of Sarepta Therapeutics in a report on Friday, September 20th. Finally, Leerink Partners upped their target price on Sarepta Therapeutics from $165.00 to $230.00 and gave the stock an “outperform” rating in a research note on Monday, June 24th. Two equities research analysts have rated the stock with a hold rating, eighteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $182.95.

Sarepta Therapeutics Price Performance

NASDAQ:SRPT opened at $132.02 on Monday. The firm’s fifty day moving average is $128.78 and its two-hundred day moving average is $132.40. The firm has a market cap of $12.48 billion, a price-to-earnings ratio of 1,200.18 and a beta of 0.82. Sarepta Therapeutics has a one year low of $55.25 and a one year high of $173.25. The company has a debt-to-equity ratio of 1.05, a quick ratio of 3.19 and a current ratio of 3.90.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 EPS for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The firm had revenue of $362.90 million for the quarter, compared to analyst estimates of $394.38 million. During the same period last year, the company earned ($0.27) earnings per share. Sarepta Therapeutics’s revenue for the quarter was up 38.9% compared to the same quarter last year. Research analysts expect that Sarepta Therapeutics will post 1.45 EPS for the current year.

Insider Buying and Selling

In other Sarepta Therapeutics news, CFO Ian Michael Estepan sold 5,985 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares in the company, valued at $4,662,822.56. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other news, Director Michael Andrew Chambers bought 37,038 shares of the firm’s stock in a transaction on Friday, August 16th. The shares were bought at an average cost of $133.80 per share, for a total transaction of $4,955,684.40. Following the acquisition, the director now directly owns 284,034 shares of the company’s stock, valued at $38,003,749.20. This trade represents a 0.00 % increase in their position. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The shares were sold at an average price of $137.36, for a total transaction of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at approximately $4,662,822.56. This trade represents a 0.00 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Nordea Investment Management AB raised its position in Sarepta Therapeutics by 120.6% in the first quarter. Nordea Investment Management AB now owns 61,657 shares of the biotechnology company’s stock valued at $8,004,000 after purchasing an additional 33,711 shares during the period. Fifth Third Wealth Advisors LLC purchased a new position in Sarepta Therapeutics during the second quarter worth about $607,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Sarepta Therapeutics during the second quarter valued at about $4,771,000. Securian Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the 2nd quarter valued at approximately $1,187,000. Finally, Natixis Advisors LLC acquired a new position in shares of Sarepta Therapeutics in the 2nd quarter worth approximately $1,918,000. 86.68% of the stock is currently owned by institutional investors and hedge funds.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.